Drugs / TIGAPOTIDE
TIGAPOTIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00695851 | Mar 2005 → Mar 2009 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIGAPOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3040192 ↗ |
| Known as | PCK3145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00695851 ↗ |
| Known as | Tigapotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3040192 ↗ |
| Action | Inhibit | “giving a drug called PCK3145 can reduce the level of a protein in the blood called MMP-9” NCT00695851 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3040192 ↗ |
| Route | Intravenous | “i.v. bolus either 15 mg/m2 weekly of PCK3145.” NCT00695851 ↗ |